Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 8, 2010, Pages 1391-1410

  Grover, Sandeep ^a   Talwar, Puneet ^a   Baghel, Ruchi ^a   Kaur, Harpreet ^a   Gupta, Meenal ^a   Gourie Devi, Mandaville ^b   Bala, Kiran ^b   Sharma, Sangeeta ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

Author keywords

Menopause; Menstrual cycle; Sex hormones; Sex steroids; Single nucleotide polymorphism (SNP)

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17A1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; DRUG METABOLIZING ENZYME; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; EPILEPSY; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVE CELL EXCITABILITY; NEUROPSYCHIATRY; PATHOGENESIS; PHENOTYPIC VARIATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78851470248     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31119     Document Type: Review

References (209)

1. Adjei AA, Weinshilboum RM. 2002. Catecholestrogen sulfation: Possible role in carcinogenesis. Biochem Biophys Res Commun 292: 402-408.
2. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, et al. 2002. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61: 586-594.
3. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, et al. 2004. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders ESEMeD project. Acta Psychiatr Scand Suppl 420: 21-27.
4. Arabia G, Zappia M, Bosco D, Crescibene L, et al. 2002. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 23(Suppl 2): S53-S54.
5. Badawi AF, Cavalieri EL, Rogan EG. 2001. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50: 1001-1003.
6. Baldereschi M, Di Carlo A, Rocca WA, Vanni P. 2000. Parkinson's disease and Parkinsonism in a longitudinal study: Two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55: 1358-1363.
7. Ball P, Knuppen R, Haupt M, Breuer H. 1972. Interactions between estrogens and catechol amines. 3. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the ctechol-O-methyltransferases of human liver. J Clin Endocrinol Metab 34: 736-746.
8. Barnes LL, Wilson RS, Bienias JL, Schneider JA, et al. 2005. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62: 685-691.
9. Belous AR, Hachey DL, Dawling S, Roodi N, et al. 2007. Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res 67: 812-817.
10. Berlanga C, Flores-Ramos M. 2006. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95: 119-123.
11. Bonomo SM, Rigamonti AE, Giunta M, Galimberti D, et al. 2009. Menopausal transition: A possible risk factor for brain pathologic events. Neurobiol Aging 30: 71-80.
12. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. 1990. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Therap 48: 381-389.
13. Bourque M, Dluzen DE, Di Paolo T. 2009. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 30: 142-157.
14. Bracke P. 1998. Sex differences in the course of depression: Evidence from a longitudinal study of a representative sample of the Belgian population. Soc Psychiatry Psychiatr Epidemiol 33: 420-429.
15. Briellmann RS, Berkovic SF, Jackson GD. 2000. Men may be more vulnerable to seizure-associated brain damage. Neurology 55: 1479-1485.
16. Burger HG, Hale GE, Dennerstein L, Robertson DM. 2008. Cycle and hormone changes during perimenopause: The key role of ovarian function. Menopause 15: 603-612.
17. Bushnell CD. 2005. Oestrogen and stroke in women: Assessment of risk. Lancet Neurol 4: 743-751.
18. Butler HT, Warden DR, Hogervorst E, Ragoussis J, et al. 2009. Association of the aromatase gene with Alzheimer's disease in women. Neurosci Lett 468: 202-206.
19. Carlini EJ, Raftogianis RB, Wood TC, Jin F, et al. 2001. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11: 57-68.
20. Carroll RS, Zhang J, Black PM. 1999. Expression of estrogen receptors alpha and beta in human meningiomas. J Neuro-Oncol 42: 109-116.
21. Chen TC, Leviton A. 1994. Headache recurrence in pregnant women with migraine. Headache 34: 107-110.
22. Chen J, Lipska BK, Halim N, Ma QD, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase COMT: Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75: 807-821.
23. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, et al. 2007. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res 76: 60-65.
24. Colson NJ, Lea RA, Quinlan S, MacMillan J, et al. 2004. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics 5: 129-133.
25. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, et al. 1998. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339: 285-291.
26. Confavreux C, Vukusic S, Adeleine P. 2003. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126: 770-782.
27. Cosimo MR, Garcia-Segura LM. 2010. Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection. Horm Behav 57: 2-11.
28. Coughtrie MW. 2002. Sulfation through the looking glass-Recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2: 297-308.
29. Cribb AE, Knight MJ, Dryer D, Guernsey J, et al. 2006. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15: 551-558.
30. Cucurachi L, Devetak M, Torelli P, Lambru G, et al. 2006. Gender ratio of migraine without aura: Observations over time. Neurol Sci 27: 47-50.
31. De Vivo I, Hankinson SE, Li L, Colditz GA, et al. 2002. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11: 489-492.
32. Deecher D, Andree TH, Sloan D, Schechter LE. 2008. From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 33: 3-17.
33. Dluzen D, Horstink M. 2003. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: Laboratory and clinical studies. Endocrine 21: 67-75.
34. Dodick DW, Lipton RB, Goadsby PJ, Tfelt-Hansen P, et al. 2008. Predictors of migraine headache recurrence: A pooled analysis from the eletriptan database. Headache 48: 184-193.
35. Dunning AM, Dowsett M, Healey CS, Tee L, et al. 2004. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96: 936-945.
36. Dutheil F, Beaune P, Loriot MA. 2008. Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90: 426-436.
37. Dworkin RJ, Adams GL. 1984. Pharmacotherapy of the chronic patient: Gender and diagnostic factors. Community Mental Health J 20: 253-261.
38. Eastwood H, Brown KM, Markovic D, Pieri LF. 2002. Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa. Mol Psychiatry 7: 86-89.
39. Eley TC, Tahir E, Angleitner A, Harriss K, et al. 2003. Association analysis of MAOA and COMT with neuroticism assessed by peers. Am J Med Genet Part B 120B: 90-96.
40. Enoch MA, Xu K, Ferro E, Harris CR, et al. 2003. Genetic origins of anxiety in women: A role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 13: 33-41.
41. Espeland MA, Rapp SR, Shumaker SA, Brunner R, et al. 2004. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 291: 2959-2968.
42. Fahndrich E, Coper H, Christ W, Helmchen H, et al. 1980. Erythrocyte COMT-activity in patients with affective disorders. Acta Psychiatr Scand 61: 427-437.
43. Farage MA, Neill S, MacLean AB. 2009. Physiological changes associated with the menstrual cycle: A review. Obstet Gynecol Surv 64: 58-72.
44. Fava M, Abraham M, Alpert J, Nierenberg AA, et al. 1996. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord 38: 129-133.
45. Feigelson HS, Shames LS, Pike MC, Coetzee GA, et al. 1998. Cytochrome P450c17alpha gene CYP17 polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58: 585-587.
46. Frank E, Carpenter LL, Kupfer DJ. 1988. Sex differences in recurrent depression: Are there any that are significant? Am J Psychiatry 145: 41-45.
47. Freeman EW, Sammel MD, Liu L, Gracia CR, et al. 2004. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 61: 62-70.
48. Freeman EW, Sammel MD, Lin H, Nelson DB. 2006. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 63: 375-382.
49. Freeman EW, Sammel MD, Lin H, Gracia CR, et al. 2008. Symptoms in the menopausal transition: Hormone and behavioral correlates. Obstet Gynecol 111: 127-136.
50. Gao S, Hendrie HC, Hall KS, Hui S. 1998. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 55: 809-815.
51. Garcia-Closas M, Herbstman J, Schiffman M, Glass A, et al. 2002. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 102: 172-178.
52. Geng YG, Su QR, Su LY, Chen Q, et al. 2007. Comparison of the polymorphisms of androgen receptor gene and estrogen alpha and beta gene between adolescent females with first-onset major depressive disorder and controls. Int J Neurosci 117: 539-547.
53. Gibbs RB, Aggarwal P. 1998. Estrogen and basal forebrain cholinergic neurons: Implications for brain aging and Alzheimer's disease-related cognitive decline. Horm Behav 34: 98-111.
54. Glassman AH, Perel JM, Shostak M, Kantor SJ, et al. 1977. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34: 197-204.
55. Goldstein JM, Link BG. 1988. Gender and the expression of schizophrenia. J Psychiatr Res 22: 141-155.
56. Goldstein JM, Cohen LS, Horton NJ, Lee H, et al. 2002. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 110: 27-37.
57. Granella F, Sances G, Zanferrari C, Costa A, et al. 1993. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache 33: 385-389.
58. Green S, Walter P, Kumar V, Krust A, et al. 1986. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320: 134-139.
59. Grover S, Talwar P, Gourie-Devi M, Gupta M, et al. 2010. Genetic polymorphism in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics (in press).
60. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, et al. 2007. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 78: 819-824.
61. Hafner H. 2003. Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl 2): 17-54.
62. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, et al. 1999. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59: 1015-1020.
63. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, et al. 2000. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87: 204-210.
64. Halbreich U. 2003. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 28(Suppl 3): 55-99.
65. Hamed SA. 2008. Neuroendocrine hormonal conditions in epilepsy: Relationship to reproductive and sexual functions. Neurologist 14: 157-169.
66. Hamilton SP, Slager SL, Heiman GA, Deng Z, et al. 2002. Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biol Psychiatry 51: 591-601.
67. Hanna IH, Dawling S, Roodi N, Guengerich FP, et al. 2000. Cytochrome P450 1B1 CYP1B1 pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60: 3440-3444.
68. Harden CL, Herzog AG, Nikolov BG, Koppel BS, et al. 2006. Hormone replacement therapy in women with epilepsy: A randomized, double-blind, placebo-controlled study. Epilepsia 47: 1447-1451.
69. Haskell SG, Richardson ED, Horwitz RI. 1997. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature. J Clin Epidemiol 50: 1249-1264.
70. Hawkins SA, McDonnell GV. 1999. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67: 148-152.
71. Hayes CL, Spink DC, Spink BC, Cao JQ, et al. 1996. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93: 9776-9781.
72. Herzog AG. 2008. Catamenial epilepsy: Definition, prevalence pathophysiology and treatment. Seizure 17: 151-159.
73. Hong J, Shu-Leong H, Tao X, Lap-Ping Y. 1998. Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport 9: 2861-2864.
74. Huang R, Poduslo SE. 2006. CYP19 haplotypes increase risk for Alzheimer's disease. J Med Genet 43: e42.
75. Isoe-Wada K, Maeda M, Yong J, Adachi Y, et al. 1999. Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia. Eur J Neurol 6: 431-435.
76. Jorm AF, Korten AE, Henderson AS. 1987. The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr Scand 76: 465-479.
77. Josefsson A, Berg G, Nordin C, Sydsjo G. 2001. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 80: 251-255.
78. Joshi G, Pradhan S, Mittal B. 2009. Role of the oestrogen receptor ESR1 PvuII and ESR1 325 C->G and progesterone receptor PROGINS polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalalgia 30: 311-320.
79. Kane FJ Jr, Lipton MA, Ewing JA. 1969. Hormonal influences in female sexual response. Arch Gen Psychiatry 20: 202-209.
80. Kawas C, Resnick S, Morrison A, Brookmeyer R, et al. 1997. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521.
81. Kendell RE, Chalmers JC, Platz C. 1987. Epidemiology of puerperal psychoses. Br J Psychiatry 150: 662-673.
82. Kessler RC, McGonagle KA, Zhao S, Nelson CB, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
83. Khan A, Brodhead AE, Schwartz KA, Kolts RL, et al. 2005. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25: 318-324.
84. King SR. 2008. Emerging roles for neurosteroids in sexual behavior and function. J Androl 29: 524-533.
85. Kipp M, Beyer C. 2009. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 30: 188-200.
86. Kisselev P, Schunck WH, Roots I, Schwarz D. 2005. Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res 65: 2972-2978.
87. Knight AH, Rhind EG. 1975. Epilepsy and pregnancy: A study of 153 pregnancies in 59 patients. Epilepsia 16: 99-110.
88. Kravitz HM, Janssen I, Lotrich FE, Kado DM, et al. 2006a. Sex steroid hormone gene polymorphisms and depressive symptoms in women at midlife. Am J Med 119: S87-S93.
89. Kravitz HM, Meyer PM, Seeman TE, Greendale GA, et al. 2006b. Cognitive functioning and sex steroid hormone gene polymorphisms in women at midlife. Am J Med 119: S94-S102.
90. Kristensen VN, Borresen-Dale AL. 2000. Molecular epidemiology of breast cancer: Genetic variation in steroid hormone metabolism. Mut Res 462: 323-333.
91. Kuhl H. 2005. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric 8(Suppl 1): 3-63.
92. Kulkarni J, de Castella A, Smith D, Taffe J, et al. 1996. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20: 247-252.
93. Kumar R, Robson KM. 1984. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 144: 35-47.
94. Labelle A, Light M, Dunbar F. 2001. Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response. Can J Psychiatry 46: 534-541.
95. Lasiuk GC, Hegadoren KM. 2007. The effects of estradiol on central serotonergic systems and its relationship to mood in women. Biol Res Nurs 9: 147-160.
96. Lee AJ, Cai MX, Thomas PE, Conney AH, et al. 2003. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144: 3382-3398.
97. Leung A, Chue P. 2000. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 401: 3-38.
98. Lin GF, Ma QW, Zhang DS, Zha YL, et al. 2003. Polymorphism of alpha-estrogen receptor and aryl hydrocarbon receptor genes in dementia patients in Shanghai suburb. Acta Pharmacol Sin 24: 651-656.
99. Lindamer LA, Buse DC, Lohr JB, Jeste DV. 2001. Hormone replacement therapy in postmenopausal women with schizophrenia: Positive effect on negative symptoms? Biol Psychiatry 49: 47-51.
100. Livonen S, Corder E, Lehtovirta M, Helisalmi S, et al. 2004. Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology 62: 1170-1176.
101. Luconi M, Forti G, Baldi E. 2002. Genomic and nongenomic effects of estrogens: Molecular mechanisms of action and clinical implications for male reproduction. J Steroid Biochem Mol Biol 80: 369-381.
102. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, et al. 2005. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 14: 1521-1527.
103. Lyons KE, Hubble JP, Troster AI, Pahwa R, et al. 1998. Gender differences in Parkinson's disease. Clin Neuropharmacol 21: 118-121.
104. MacGowan SH, Wilcock GK, Scott M. 1998. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 13: 625-630.
105. MacGregor EA. 2005. Female sex hormones and migraine. Rev Neurol Paris 161: 677-678.
106. McEwen B. 2002. Estrogen actions throughout the brain. Recent Prog Horm Res 57: 357-384.
107. McFayden MC, Melvin WT, Murray GI. 1998. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol 55: 825-830.
108. McGrath M, Kawachi I, Ascherio A, Colditz GA, et al. 2004. Association between catechol-O-methyltransferase and phobic anxiety. Am J Psychiatry 161: 1703-1705.
109. Mellon SH, Deschepper CF. 1993. Neurosteroid biosynthesis: Genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res 629: 283-292.
110. Mendelson CR, Means GD, Mahendroo MS, Corbin CJ, et al. 1990. Use of molecular probes to study regulation of aromatase cytochrome P-450. Biol Reprod 42: 1-10.
111. Morrison MF, Kallan MJ, Ten Have T, Katz I, et al. 2004. Lack of efficacy of estradiol for depression in postmenopausal women: A randomized, controlled trial. Biol Psychiatry 55: 406-412.
112. Mortimer AM. 2007. Relationship between estrogen and schizophrenia. Expert Rev Neurotherap 7: 45-55.
113. Mucchiut M, Belgrado E, Cutuli D, Antonini A, et al. 2004. Pramipexole-treated Parkinson's disease during pregnancy. Movement Disord 19: 1114-1115.
114. Nagar S, Walther S, Blanchard RL. 2006. Sulfotransferase SULT 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol 69: 2084-2092.
115. Napoli N, Villareal DT, Mumm S, Halstead L, et al. 2005. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 20: 232-239.
116. Napoli N, Rini GB, Serber D, Giri T, et al. 2009. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. Bone 44: 442-448.
117. Nappi RE, Cagnacci A, Granella F, Piccinini F, et al. 2001. Course of primary headaches during hormone replacement therapy. Maturitas 38: 157-163.
118. Nelson HD. 2008. Menopause. Lancet 371: 760-770.
119. Neri I, Granella F, Nappi R, Manzoni GC, et al. 1993. Characteristics of headache at menopause: A clinico-epidemiologic study. Maturitas 17: 31-37.
120. Noonan CW, Kathman SJ, White MC. 2002. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 58: 136-138.
121. Nott PN. 1982. Psychiatric illness following childbirth in Southampton: A case register study. Psychol Med 12: 557-561.
122. Olsen L, Rasmussen HB, Hansen T, Bagger YZ, et al. 2006. Estrogen receptor alpha and risk for cognitive impairment in postmenopausal women. Psychiatr Genet 16: 85-88.
123. Orton SM, Herrera BM, Yee IM, Valdar W, et al. 2006. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 5: 932-936.
124. Osterlund MK, Hurd YL. 2001. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol 64: 251-267.
125. Otani K. 1985. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 39: 33-41.
126. Oterino A, Toriello M, Cayon A, Castillo J, et al. 2008. Multilocus analyses reveal involvement of the ESR1, ESR2, and FSHR genes in migraine. Headache 48: 1438-1450.
127. Parker G, Parker K, Austin MP, Mitchell P, et al. 2003. Gender differences in response to differing antidepressant drug classes: Two negative studies. Psychol Med 33: 1473-1477.
128. Paynter RA, Hankinson SE, Colditz GA, Kraft P, et al. 2005. CYP19 aromatase haplotypes and endometrial cancer risk. Int J Cancer 116: 267-274.
129. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. 1991. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231-235.
130. Perugi G, Musetti L, Simonini E, Piagentini F, et al. 1990. Gender-mediated clinical features of depressive illness. The importance of temperamental differences. Br J Psychiatry 157: 835-841.
131. Pike CJ, Carroll JC, Rosario ER, Barron AM. 2009. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 30: 239-258.
132. Pirskanen M, Hiltunen M, Mannermaa A, Helisalmi S, et al. 2005. Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet 13: 1000-1006.
133. Porrello E, Monti MC, Sinforiani E, Cairati M., et al. 2006. Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur J Neurol 13: 639-644.
134. Queiroz LP, Peres MF, Piovesan EJ, Kowacs F, et al. 2009. A nationwide population-based study of migraine in Brazil. Cephalalgia 29: 642-649.
135. Quinn NP, Marsden CD. 1986. Menstrual-related fluctuations in Parkinson's disease. Movement Disord 1: 85-87.
136. Radhakrishnan K, Pandian JD, Santhoshkumar T, Thomas SV, et al. 2000. Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. Epilepsia 41: 1027-1035.
137. Raftogianis RB, Wood TC, Weinshilboum RM. 1999. Human phenol sulfotransferases SULT1A2 and SULT1A1: Genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 58: 605-616.
138. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, et al. 2003. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 289: 2663-2672.
139. Rasmussen BK, Olesen J. 1992. Migraine with aura and migraine without aura: An epidemiological study. Cephalalgia 12: 221-228.
140. Riecher-Rossler A, de Geyter C. 2007. The forthcoming role of treatment with oestrogens in mental health. Swiss Med Wkly 137: 565-572.
141. Riecher-Rossler A, Hafner H. 2000. Gender aspects in schizophrenia: Bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl 407: 58-62.
142. Rieder CR, Ramsden DB, Williams AC. 1998. Cytochrome P450 1B1 mRNA in the human central nervous system. Mol Pathol 51: 138-142.
143. Rigaud AS, Traykov L, Caputo L, Guelfi MC, et al. 2000. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol 7: 255-258.
144. Robinson DG, Woerner MG, Alvir JM, Geisler S, et al. 1999. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156: 544-549.
145. Rojo A, Aguilar M, Garolera MT, Cubo E, et al. 2003. Depression in Parkinson's disease: Clinical correlates and outcome. Parkinsonism Relat Disord 10: 23-28.
146. Rothe C, Koszycki D, Bradwejn J, King N, et al. 2006. Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. Neuropsychopharmacology 31: 2237-2242.
147. Rothrock JF, Parada VA, Drinkard R, Zweifler RM, et al. 2005. Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 45: 932-935.
148. Routiot T, Lurel S, Denis E, Barbarino-Monnier P. 2000. Parkinson's disease and pregnancy: Case report and literature review. J Gynécol Obstét Biol Reprod 29: 454-457.
149. Salman ED, Kadlubar SA, Falany CN. 2009. Expression and localization of cytosolic sulfotransferase SULT 1A1 and SULT1A3 in normal human brain. Drug Metab Dispos 37: 706-709.
150. Salokangas RK. 1995. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr Res 16: 7-16.
151. Sances G, Granella F, Nappi RE, Fignon A, et al. 2003. Course of migraine during pregnancy and postpartum: A prospective study. Cephalalgia 23: 197-205.
152. Sasano H, Takashashi K, Satoh F, Nagura H, et al. 1998. Aromatase in the human central nervous system. Clin Endocrinol (Oxf) 48: 325-329.
153. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, et al. 1999. The effect of estrogen replacement on early Parkinson's disease. Neurology 52: 1417-1421.
154. Savettieri G, Messina D, Andreoli V, Bonavita S, et al. 2004. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 251: 1208-1214.
155. Scaglione C, Vignatelli L, Plazzi G, Marchese R, et al. 2005. REM sleep behaviour disorder in Parkinson's disease: A questionnaire-based study. Neurol Sci 25: 316-321.
156. Schrag A, Ben-Shlomo Y, Quinn NP. 2000. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 321: 21-22.
157. Schuit SC, de Jong FH, Stolk L, Koek WN, et al. 2005. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol 153: 327-334.
158. Schupf N, Ottman R. 1997. Reproduction among individuals with idiopathic/cryptogenic epilepsy: Risk factors for spontaneous abortion. Epilepsia 38: 824-829.
159. Seeman MV. 1983. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 24: 125-128.
160. Shatalova EG, Walther SE, Favorova OO, Rebbeck TR, et al. 2005. Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: A case-series study. Breast Cancer Res 7: R909-R921.
161. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, et al. 2002. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71: 1296-1302.
162. Shumaker SA, Legault C, Rapp SR, Thal L, et al. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 289: 2651-2662.
163. Shumaker SA, Legault C, Kuller L, Rapp SR, et al. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 291: 2947-2958.
164. Sicotte NL, Liva SM, Klutch R, Pfeiffer P. 2002. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52: 421-428.
165. Singh S, Zahid M, Saeed M, Gaikwad NW, et al. 2009. NADPH:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells. J Steroid Biochem Mol Biol 117: 56-66.
166. Smith R, Studd JW. 1992. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 85: 612-613.
167. Soares CN, Poitras JR, Prouty J. 2003. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging 20: 85-100.
168. Somner J, McLellan S, Cheung J, Mak YT. 2004. Polymorphisms in the P450 c17 17-hydroxylase/17, 20-lyase and P450 c19 aromatase genes: Association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 89: 344-351.
169. Sowers MR, Wilson AL, Kardia SR, Chu J, et al. 2006a. CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal. Am J Med 119: (9 Suppl 1): S44-S51.
170. Sowers MR, Wilson AL, Kardia SR, Chu J, et al. 2006b. Aromatase gene CYP19 polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med 119: S23-S30.
171. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, et al. 2006c. Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med 119: S16-S22.
172. Sparks R, Ulrich CM, Bigler J, Tworoger SS, et al. 2004. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6: 488-498.
173. Stein MB, Fallin MD, Schork NJ, Gelernter J. 2005. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology 30: 2092-2102.
174. Stewart WF, Linet MS, Celentano DD, Van NM, et al. 1991. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol 134: 1111-1120.
175. Stillman MJ, Zajac D, Rybicki LA. 2004. Treatment of primary headache disorders with intravenous valproate: Initial outpatient experience. Headache 44: 65-69.
176. Stoffel-Wagner B, Watzka M, Schramm J, Bidlingmaier F, et al. 1999. Expression of CYP19 aromatase mRNA in different areas of the human brain. J Steroid Biochem Mol Biol 70: 237-241.
177. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, et al. 1999. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 23: 232-237.
178. Tang MX, Jacobs D, Stern Y, Marder K, et al. 1996. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432.
179. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, et al. 1994. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223: 1049-1059.
180. Thiels C, Linden M, Grieger F, Leonard J. 2005. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 20: 1-7.
181. Tsai SJ, Wang YC, Hong CJ, Chiu HJ. 2003. Association study of oestrogen receptor alpha gene polymorphism and suicidal behaviours in major depressive disorder. Psychiatr Genet 13: 19-22.
182. Tsang KL, Ho SL, Lo SK. 2000. Estrogen improves motor disability in Parkinsonian postmenopausal women with motor fluctuations. Neurology 54: 2292-2298.
183. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, et al. 2004. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13: 94-101.
184. Usall J, Suarez D, Haro JM. 2007. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 153: 225-231.
185. Venners SA, Liu X, Perry MJ, Korrick SA, et al. 2006. Urinary estrogen and progesterone metabolite concentrations in menstrual cycles of fertile women with non-conception, early pregnancy loss or clinical pregnancy. Hum Reprod 21: 2272-2280.
186. Waring SC, Rocca WA, Petersen RC, O'Brien PC, et al. 1999. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 52: 965-970.
187. Warren MP. 2007. Historical perspectives in postmenopausal hormone therapy: Defining the right dose and duration. Mayo Clin Proc 82: 219-226.
188. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, et al. 2008. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 17: 2293-2309.
189. Westberg L, Håkansson A, Melke J, Shahabi HN, et al. 2004. Association between the estrogen receptor beta gene and age of onset of Parkinson's disease. Psychoneuroendocrinology 29: 993-998.
190. Wihlback AC, Sundstrom-Poromaa I, Backstrom T. 2006. Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders. Psychopharmacology (Berl) 186: 388-401.
191. Wild JM, Martinez C, Reinshagen G, Harding GF. 1999. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40: 1784-1794.
192. Wohlfarth T, Storosum JG, Elferink AJ, van Zwieten BJ, et al. 2004. Response to tricyclic antidepressants: Independent of gender? Am J Psychiatry 161: 370-372.
193. Wojtowicz T, Lebida K, Mozrzymas JW. 2008. 17beta-estradiol affects GABAergic transmission in developing hippocampus. Brain Res 1241: 7-17.
194. Wong IC, Mawer GE, Sander JW. 1999. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 33: 1037-1042.
195. Woolley CS. 2007. Acute effects of estrogen on neuronal physiology. Annu Rev Pharmacol Toxicol 47: 657-680.
196. Worda C, Sator MO, Schneeberger C, Jantschev T, et al. 2003. Influence of the catechol-O-methyltransferase COMT codon 158 polymorphism on estrogen levels in women. Hum Reprod 18: 262-266.
197. Xie T, Ho SL, Ramsden D. 1999. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56: 31-38.
198. Yaffe K, Lui LY, Grady D, Stone K, et al. 2002. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 51: 677-682.
199. Yague JG, Munoz A, de Monasterio-Schrader P, Defelipe J, et al. 2006. Aromatase expression in the human temporal cortex. Neuroscience 138: 389-401.
200. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. 1998. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 11: 659-665.
201. Yang G, Gao YT, Cai QY, Shu XO, et al. 2005. Modifying effects of sulfotransferase 1A1 gene polymorphism on the association of breast cancer risk with body mass index or endogenous steroid hormones. Breast Cancer Res Treat 94: 63-70.
202. Young EA, Kornstein SG, Marcus SM, Harvey AT, et al. 2009. Sex differences in response to citalopram: A STAR*D report. J Psychiatr Res 43: 503-511.
203. Yue X, Lu M, Lancaster T, Cao P, et al. 2005. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 102: 19198-19203.
204. Zamani MR, Levy WB, Desmond NL. 2004. Estradiol increases delayed, N-methyl-D-aspartate receptor-mediated excitation in the hippocampal CA1 region. Neuroscience 129: 243-254.
205. Zappia M, Quattrone A. 2002. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 59: 2010.
206. Zhu BT, Lee AJ. 2005. NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids 70: 225-244.
207. Zorgdrager A, De Keyser J. 2002. The premenstrual period and exacerbations in multiple sclerosis. Eur Neurol 48: 204-206.
208. Zwain IH, Yen SS. 1999. Dehydroepiandrosterone: Biosynthesis and metabolism in the brain. Endocrinology 140: 880-887.
209. Zweifel JE, O'Brien WH. 1997. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22: 189-212.